HDAC9 and primary cutaneous T-cell non-Hodgkin lymphoma: Since we have recently shown that HDAC inhibition specifically induces CXCL8 expression in OC cells, resulting in their increased survival and proliferation [5], we wanted to determine whether HDAC inhibition by vorinostat induces the CXCL8 expression also in CTCL cells, where vorinostat has been effectively used for CTCL treatment.